Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Transfusion-Dependent Beta-Thalassemia

RICHMOND, Calif., April 27, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the California Institute for Regenerative Medicine (CIRM) has awarded an $8 million grant for Sangamo to evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia.

"CIRM plays a critical role in funding the rigorous evaluation of new stem cell therapies, and we are very pleased to receive CIRM's support for the study of ST-400 for the treatment of transfusion-dependent beta-thalassemia," said Edward Conner, M.D., chief medical officer at Sangamo. "We believe the precision, efficiency and specificity of zinc finger nuclease gene editing has the potential to differentiate ST-400 from other genomic therapies in development for this disease."

Sangamo's Investigational New Drug Application for ST-400 has been accepted by the U.S. Food and Drug Administration, and the first site is now initiated for a Phase 1/2 clinical trial. Sangamo expects to begin enrolling patients in this study in the first half of 2018.

Beta-thalassemia is an inherited blood disorder caused by mutations in the beta-globin gene that leads to reduced or absent production of adult hemoglobin, the protein in red blood cells that carries oxygen to cells throughout the body. The disorder causes the destruction of red blood cells, which results in severe anemia and reduced oxygen transport to various tissues in the body.

According to the World Health Organization, there are approximately 100,000 known beta-thalassemia patients worldwide, with ~19,000 of those in the United States and Europe.¹ The majority of these patients are transfusion-dependent, and their current standard of care includes a chronic regimen of red blood cell transfusions, which may lead to iron overload and organ damage even with daily iron chelation therapy. Allogeneic bone marrow transplant may be a treatment option for these patients if a suitable donor can be found, but carries substantial risks such as graft-versus-host disease.

Sangamo and Bioverativ, a Sanofi Company, are developing ST-400 as part of an exclusive worldwide collaboration to develop and commercialize zinc finger nuclease (ZFN)-mediated gene-edited cell therapies for the treatment of transfusion-dependent beta-thalassemia and sickle cell disease.

About ST-400 and the Phase 1/2 Clinical Trial
ST-400 is an autologous cell therapy that involves gene editing of a patient's own hematopoietic stem cells (HSCs) using zinc finger nuclease (ZFN) technology. It is being developed with the aim of providing a one-time treatment for people with transfusion-dependent beta-thalassemia by increasing production of fetal hemoglobin, which can more effectively carry oxygen and protect thalassemic red blood cells from premature destruction, potentially eliminating the need for chronic blood transfusions. As part of the Phase 1/2 clinical trial protocol, a patient's HSCs are isolated from the blood, and the cells then undergo ex vivo gene editing using ZFNs to modify a specific sequence of the BCL11A gene that suppresses fetal hemoglobin production in erythrocytes. Following a conditioning regimen, patients will be infused with their own modified HSCs, with the goal of producing increased amounts of fetal hemoglobin to compensate for the decrease in functional adult hemoglobin levels. As a result, ST-400 could potentially reduce or eliminate the need for chronic blood transfusions and ameliorate the complications from major organ damage due to iron overload.

About the California Institute for Regenerative Medicine (CIRM)
CIRM, California's stem cell institute, was created by the voters of California in 2004 when they overwhelmingly passed Proposition 71, which authorized $3 billion in funding for stem cell research in California. The institute funds stem cell research at institutions and companies throughout California (as well as institutions and companies outside of the state that conduct a portion of their research in California) with the goal of accelerating treatments to patients with unmet medical needs.

About Sangamo Therapeutics 
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, lysosomal storage disorders MPS I and MPS II, and beta-thalassemia. Sangamo has exclusive, global collaboration and license agreements with Kite, a Gilead Company, to develop next-generation autologous and allogeneic engineered cell therapies for the treatment of cancer using zinc finger nuclease genome editing technology; with Pfizer Inc. for gene therapy programs for Hemophilia A; with Bioverativ, a Sanofi Company, for hemoglobinopathies, including beta-thalassemia and sickle cell disease; and with Shire International GmbH to develop therapeutics for Huntington's disease. For more information about Sangamo, visit the Company's website at www.sangamo.com.

Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential for the precision, efficiency and specificity of zinc finger nuclease gene editing to differentiate ST-400 from other genomic therapies in development for this disease, the potential for ST-400 to provide a one-time treatment option for people with beta-thalassemia, the planned Phase 1/2 clinical trial of ST-400 and the expectation that the Company will begin enrolling patients in the first half of 2018. These forward-looking statements are based on Sangamo's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties inherent in the Company's business, which include, without limitation, risks and uncertainties associated with: gene therapy product candidate development and the inherent uncertainty of clinical success, including the risks that Sangamo and/or Bioverativ may encounter unanticipated toxicity or adverse events in, or fail to demonstrate the efficacy of ST-400 in, clinical development and that the planned Phase 1/2 clinical trial may otherwise fail to validate and support the tolerability and efficacy of ST-400; Sangamo's substantial dependence on the clinical success of its lead therapeutic programs; the initiation, enrollment and completion of the stages of its clinical trials, including Sangamo's potential inability to enroll the planned Phase 1/2 clinical trial of ST-400 in a timely manner or at all; technological challenges; the lengthy and uncertain regulatory approval process; Sangamo's and Bioverativ's ability to develop a commercially viable ST-400 product or other products under the collaboration; technological developments by competitors and others in the genomic therapy field; and Sangamo's dependence on its collaboration with Bioverativ for the development of ST-400 and its ability to maintain its collaboration with Bioverativ. A more detailed discussion of these and other risks and uncertainties may be found under the caption "Risk Factors" and elsewhere in Sangamo's SEC filings and reports, including Sangamo's Annual Report on Form 10-K for the year ended December 31, 2017 and future filings and reports by Sangamo. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo Therapeutics, Inc.

Related Links

http://www.sangamo.com